Fig. 9: Proposed model for the role of PPP2R2B in determining the sensitivity to HER2-targeted therapies.
From: EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
EZH2-mediated repression (left) of PPP2R2B leads to the absence of functional PPP2R2B-containing PP2A, and thus residual p-4EBP1 and p-p70S6K and tumorigenesis, with HER2-targeted therapies. Accordingly, inhibition of EZH2 (right) restores PPP2R2B expression and functional PPP2R2B-containing PP2A that reduces phosphorylation of 4EBP1 and p70S6K and thus inhibits tumorigenesis under anti-HER2 treatments.
